Drug manufacturer Eli Lilly announced a new round of refunds for Humulin, a brand-name insulin, following a 340B ceiling price [...] …
Year: 2024
Fourteen years after the Congressional deadline, the long-anticipated revision to the 340B Administrative Dispute Resolution (ADR) process officially took effect [...] …
A U.S. senator introduced a bill to extend 340B eligibility to certain outpatient rural hospitals with emergency services, mirroring a [...] …
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...] …
HHS and Congress should each take long-proposed actions—including a contentious action to curb certain Part B prescribing incentives—to better ensure [...] …
A key argument in AstraZeneca’s lawsuit challenging Arkansas’ 340B contract pharmacy access law has already been rejected by a higher [...] …
Drug manufacturer Novartis uses contradictory, “whiplash-inducing” arguments in its lawsuit challenging Mississippi’s 340B contract pharmacy law, hospital groups told a [...] …
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June [...] …
340B INDUSTRY LEADER SPOTLIGHT
Mesfin Tegenu, Founder & CEO, RxParadigm
Q: Where did you grow up?
I grew up in Addis Ababa, the capital city of Ethiopia.
Q: Where did you go to college/graduate school?
I completed my undergraduate studies at Addis Ababa University in Ethiopia and attended graduate school at St. John’s University in Queens, New York.
Q: What are your favorites?
Food: I mostly enjoy
…SPONSORED CONTENT
TIP: To avoid unnecessary audit findings, it is critically important to review OPAIS data regularly.
HRSA audit